[1]Liu,Zilei;Li,Jie;Li,Suhua;Li,Gencheng;Sharpless,K.Barry;Wu,Peng[JournaloftheAmericanChemicalSociety,2018,vol.140,#8,p.2919-2925]
[1]CurrentPatentAssignee:SOUTHEASTUNIVERSITY-CN107163029,2017,ALocationinpatent:Paragraph0049;0081;0082;0083;0084;0085
[1]CurrentPatentAssignee:SOUTHEASTUNIVERSITY-CN107163029,2017,A
[1]Patent:CN107163029,2017,A
[1]Patent:CN107163029,2017,A
Title: Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD.
Journal: Human molecular genetics 20150715
Title: Shimamura T, et al. Ganetespib (STA-9090), a Non-Geldanamycin HSP90 Inhibitor, has Potent Antitumor Activity in In Vitro and In Vivo Models of Non-Small Cell Lung Cancer. Clin Cancer Res. 2012 Jul 17.
Title: Ying W, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012 Feb;11(2):475-84.
Title: London CA, et al. Phase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer.PLoS One. 2011;6(11):e27018.
Title: Proia DA, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 2011 Apr 14;6(4):e18552.
Title: Stewart E, et al. Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer Cell. 2018 Sep 10;34(3):411-426.e19.
